Lilly’s retatrutide creeps closer to market for sleep apnea
Expectations for the launch of Eli Lilly’s triple agonist retatrutide in obesity, due next year, are at fever pitch. But the company is also lining up data in other indications with the aim of eventually ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.